CRUK: Phase II trial of ginisortamab with (1) 1st-line gemcitabine + nab-paclitaxel (AG) or (2) MEK inhibitor as maintenance therapy in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC)
No Thumbnail Available
All Authors
Evans, T.
Guren, T.
Baxter, M.
Christie, A.
Froeling, F.
Lamarca, A.
Collinson, F.
Goldstein, R.
Macarulla, T.
Miller, P.
LTHT Author
Collinson, Fiona
LTHT Department
Oncology
Leeds Cancer Centre
Leeds Cancer Centre
Contributor Profession (Non Medical)
Publication Date
2026
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
Journal
Journal of Clinical Oncology